InvestorsHub Logo
Followers 8
Posts 205
Boards Moderated 0
Alias Born 03/23/2014

Re: None

Thursday, 01/26/2017 9:11:59 PM

Thursday, January 26, 2017 9:11:59 PM

Post# of 75453
Question: Did any of today's doom & gloom Einsteins happen to notice the DECLINING RATE at which shares were issued for conversion of debt during Q4? ...

45,600,000 in September
30,000,000 in October
15,000,000 in November

All the while the company was smartly spending nearly six times more on Research and Development in 2016 vs. 2015 and two times more in Consulting Expenses to position the business for a breakout year of rapid growth ahead as CBD awareness spreads to the remaining 90% of the population.

Now with gross profit being up to $1,859,965 per year, 10 times the positive income of 2015, new and improved products and web sites on the way, greatly expanded hemp growing capacity, high customer base retention, 10,000 new customers in 2016, a minimum of 35,000 new customers expected in 2017 and James Ballas' stated commitment to balance new income going forward between paying debt in cash and growing the business it's reasonable to assume that the company will be financially capable of paying the paltry remaining $557,814 owed to Common Sense Holdings from now through 2018 with CASH instead of shares going forward.

So congratulations to all who locked in their 100% gains today. That's great for you and great for those who bought from you too. A win-win trade!

But, sorry, no, you can't have any of my shares for your next flip or to help cover today's 7,322,846 shorts.

This is no run-down software company. This is Endo BioSciences, Inc. And, yes, in case you missed the news, a formal name change and new ticker is one of management's top priorities for this quarter and they will deliver this catalyst soon. Count on it!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent UBQU News